PAASHEUVELWEG 25A, AMSTERDAM, P7
Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington’s Disease
Annual Report to Security Holders
Provides Regulatory Update on AMT-130 for Huntington’s Disease
Investor Presentation
Announces Type A Meeting Scheduled with FDA
Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Initial Statement of Beneficial Ownership